Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 14/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102194 | 0.91 | MPL (0.84) | MPLCHEK2RORC | |
| SCHEMBL1091924 | 0.91 | MPL (1.00) | MPLDAPK3NTRK1PIM1FLT3 | |
| SCHEMBL1092180 | 0.84 | MPL (1.00) | MPLCHEK2AR | |
| SCHEMBL1102185 | 0.82 | MPL (0.84) | MPL | |
| SCHEMBL1091719 | 0.80 | MPL (0.67) | MPLCHEK2MAPK14ARRORC | |
| SCHEMBL1091867 | 0.80 | MPL (0.67) | MPLAR | |
| SCHEMBL1090226 | 0.78 | MPL (0.63) | MPLDAPK3NTRK1PIM1FLT3 | |
| SCHEMBL1091483 | 0.77 | MPL (0.63) | MPLMAPK14 | |
| Trifluoroacetic Acid SCHEMBL1091774 | 0.77 | MPL (0.64) | MPL | |
| SCHEMBL1102243 | 0.77 | MPL (0.64) | MPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| EP-1910338-B1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2010-08-25 | — | — | EP | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | MPL, TPO, THPO | MPL 1/4885CHEK2 961/4885MAPK14 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.